NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis $0.99 +0.15 (+17.86%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Karyopharm Therapeutics Stock (NASDAQ:KPTI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KPTI alerts:Sign Up Key Stats Today's Range$0.87▼$1.1350-Day Range$0.70▼$0.9052-Week Range$0.62▼$1.95Volume8.37 million shsAverage Volume1.27 million shsMarket Capitalization$123.34 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More… Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Karyopharm Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreKPTI MarketRank™: Karyopharm Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 171st out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKaryopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Karyopharm Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($0.93) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.13% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 27.2, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 5.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-1.11 Percentage of Shares Shorted14.13% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 27.2, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 5.32%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.78 News SentimentKaryopharm Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,530.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Stock News HeadlinesKaryopharm to Report Third Quarter 2024 Financial Results on November 5, 2024October 31 at 8:00 AM | prnewswire.comKaryopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in MyelofibrosisOctober 31 at 7:30 AM | prnewswire.comtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.October 31, 2024 | Traders Agency (Ad)Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024October 30 at 4:30 PM | prnewswire.comHighbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics SharesOctober 26, 2024 | finance.yahoo.comPiper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)October 23, 2024 | markets.businessinsider.comAntengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the CountryOctober 17, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | prnewswire.comSee More Headlines KPTI Stock Analysis - Frequently Asked Questions How have KPTI shares performed this year? Karyopharm Therapeutics' stock was trading at $0.8650 at the beginning of 2024. Since then, KPTI shares have increased by 15.6% and is now trading at $1.0001. View the best growth stocks for 2024 here. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its earnings results on Tuesday, August, 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.09. The firm earned $42.79 million during the quarter, compared to analyst estimates of $36.07 million. Who are Karyopharm Therapeutics' major shareholders? Top institutional shareholders of Karyopharm Therapeutics include Exchange Traded Concepts LLC (0.18%). Insiders that own company stock include Richard A Paulson, Michael Mason, Reshma Rangwala, Stuart Poulton, Michael Mano, Sohanya Roshan Cheng, Stephen Mitchener, Garen G Bohlin, Deepika Pakianathan, Sharon Shacham, Jatin Shah and Michael Kauffman. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS). Company Calendar Last Earnings8/06/2024Today10/31/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$7.00 Low Stock Price Target$3.00 Potential Upside/Downside+405.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,100,000.00 Net Margins-61.72% Pretax Margin-61.53% Return on EquityN/A Return on Assets-38.72% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.56 Sales & Book Value Annual Sales$145.67 million Price / Sales0.85 Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-0.83Miscellaneous Outstanding Shares124,616,000Free Float119,323,000Market Cap$123.34 million OptionableOptionable Beta0.20 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:KPTI) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.